The Radiation and Free Radical Research Core focuses on providing state of the art technologies to HCCC investigators studying the role of oxidative stress and redox biology as they relate to cancer biology and cancer therapy. There is growing evidence that oxidative stress and redox biology are critical determinants of cancer biology including the processes of initiation, promotion, and progression to malignancy as well as the prevention and treatment of cancer. The Radiation and Free Radical Research Core (RFRRC) was established to provide easy access to free radical and radiation biology expertise, reagents, technologies, and analysis for HCCC investigators doing basic, pre-clinical, and clinical research. The three basic services provided by the core are: 1) Ionizing radiation services and phosphorimaging as well as cell cycle analytical tools critical to understanding cellular responses to radio-chemo-therapy. 2) Electron paramagnetic resonance spectroscopy and other detection methodologies for measuring free radicals, singlet oxygen, nitric oxide and the array of related oxidants and oxidative damage products. 3) Antioxidant enzyme services to provide easy access to technologies for modifying and measuring molecules responsible for pro-oxidant formation, metabolism of reactive oxygen species, and mediators of redox biology including: anti-oxidant proteins, small molecular weight cellular thiols and reductants, as well as redox mediated signaling and gene expression pathways governing growth, differentiation, and cell injury processes. The RFRRC is unique in its ability to provide HCCC members easy access to such knowledge, reagents and resources. The expertise for the RFRRC is based in the Free Radical Cancer Biology Program, but the RFRRC had more than 80 HCCC members use its facilities from 2005-2009, representing all 6 HCCC programs. During this period of support the research activities facilitated by the services in the RFFRC significantly contributed to 135 peer reviewed publications.
There is ongoing recognition of the role free radicals and oxidate events play in both carcinogenesis and cancer therapy. The Radiation and Free Radical Research Core provides HCCC members with the ability to irradiate cells, analyze free radical status within cells and assess the status of anti-oxidant enzymes. The research supported by the Radiation and Free Radical Research Core is, therefore, highly cancer relevant.
|Meyerholz, David K; Ofori-Amanfo, Georgina K; Leidinger, Mariah R et al. (2017) Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem 65:607-618|
|Ebbert, Jon O; Little, Melissa A; Klesges, Robert C et al. (2017) Step Care treatment for smoking cessation. Health Educ Res 32:1-11|
|Sfeir, J G; Drake, M T; LaPlant, B R et al. (2017) Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J 7:e526|
|Mohiuddin, I; Allen, B G (2017) A Single-Institution Experience in Treating Thymic Carcinoma. Int J Radiat Oncol Biol Phys 98:229|
|Miller, Benjamin J (2017) CORR Insights®: Is It Appropriate to Treat Sarcoma Metastases With Intramedullary Nailing? Clin Orthop Relat Res 475:218-220|
|Huang, Jianguo; Chen, Mark; Whitley, Melodi Javid et al. (2017) Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nat Commun 8:15999|
|Jethava, Yogesh S; Barlogie, Bart; Tricot, Guido J (2017) Drug Combinations with Transplantation for Myeloma. N Engl J Med 377:91-2|
|Gilbertson-White, Stephanie; Bohr, Nicole; Wickersham, Karen E (2017) Conducting Biobehavioral Research in Patients With Advanced Cancer: Recruitment Challenges and Solutions. Biol Res Nurs 19:481-490|
|Rogers, Laura M; Mott, Sarah L; Smith, Brian J et al. (2017) Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. Clin Cancer Res 23:954-961|
|Eppsteiner, Robert W; Fowlkes, Jonathan W; Anderson, Carryn M et al. (2017) Aggressive Salivary Malignancies at Early Stage: Outcomes and Implications for Treatment. Ann Otol Rhinol Laryngol 126:525-529|
Showing the most recent 10 out of 831 publications